Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / BioArctic
Company

BioArctic

Tracked across 3 events · 26 articles · First seen Apr 21, 2026 · Last active May 15, 2026

Sentiment
17
Attention
4
Events
3
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (3)
2 0
Business
BioArctic Q1 2026 Report Presentation
BioArctic will publish its first quarter report for January - March 2026 on May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic is inviting investors, analysts, and media to a webcast…
Impact: BioArctic is publishing its first quarter report for January - March 2026 and inviting investors, analysts, and media to a webcast and teleconference to present and comment on the report.
May 13, 2026 · 7 articles
4 70
Business
Eisai Projects Leqembi Revenue Growth
Eisai, in collaboration with BioArctic, announced a projected revenue of JPY 143.5 billion (approximately SEK 8.4 billion) for their Alzheimer's drug, Lecanemab, for fiscal year 2026 (April 2026 - March 2027). This represents a 63%…
Impact: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
4 -20
Regulatory
Leqembi Iqlik PDUFA Date Extended
The United States — Food and Drug Administration has extended the review period for Eisai's supplemental Biologics License Application (sBLA) for Lecanemab Iqlik, a once-weekly subcutaneous injection of lecanemab irmb for early Alzheimer's disease. The…
Impact: BioArctic, in collaboration with Eisai, developed Lecanemab. The extension of the PDUFA date for Lecanemab Iqlik's sBLA could delay potential revenue streams for BioArctic.
May 08, 2026 · 13 articles
Key Actions (2)
100 BioArctic published annual reportBioArctic Q1 2026 Report...
90 BioArctic inviteBioArctic Q1 2026 Report...
Relationships (2)
Eisai licensor ↔ BioArctic BioArctic is the original developer and licensor of the Alzheimer's drug Leqembi
Eisai licensee ↔ BioArctic Eisai holds the license to clinically develop and commercialize BioArctic's Alzh
NEWSDESK
Track BioArctic live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.